다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology, v.11 no.1, 2013년, pp.7 - 12
An, Hoyoung (Department of Psychiatry, Jeju Medical Center, Jeju, Korea.) , Sohn, Hyunjoo (Department of Family Medicine, Jeju National University School of Medicine, Jeju, Korea.) , Chung, Seockhoon (Department of Psychiatry, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.)
AI-Helper
A safe and effective way to control weight in patients with affective disorders is needed, and phentermine is a possible candidate. We performed a PubMed search of articles pertaining to phentermine, sibutramine, and affective disorders. We compared the studies of phentermine with those of sibutrami...
1 Berkowitz RI Fabricatore AN Obesity, psychiatric status, and psychiatric medications Psychiatr Clin North Am 2011 34 747 764 22098801
2 de Wit L Luppino F van Straten A Penninx B Zitman F Cuijpers P Depression and obesity: a meta-analysis of community-based studies Psychiatry Res 2010 178 230 235 20462641
3 Fagiolini A Frank E Houck PR Mallinger AG Swartz HA Buysse DJ Prevalence of obesity and weight change during treatment in patients with bipolar I disorder J Clin Psychiatry 2002 63 528 533 12088166
4 Keck PE McElroy SL Bipolar disorder, obesity, and pharmacotherapy-associated weight gain J Clin Psychiatry 2003 64 1426 1435 14728103
5 McElroy SL Frye MA Suppes T Dhavale D Keck PE Jr Leverich GS Correlates of overweight and obesity in 644 patients with bipolar disorder J Clin Psychiatry 2002 63 207 213 11926719
6 McElroy SL Kotwal R Malhotra S Nelson EB Keck PE Nemeroff CB Are mood disorders and obesity related? A review for the mental health professional J Clin Psychiatry 2004 65 634 651 15163249
7 Hirschfeld RM Long-term side effects of SSRIs: sexual dysfunction and weight gain J Clin Psychiatry 2003 64 Suppl 18 20 24 14700451
8 McIntyre RS McCann SM Kennedy SH Antipsychotic metabolic effects: weight gain, diabetes mellitus, and lipid abnormalities Can J Psychiatry 2001 46 273 281 11320682
9 Nathan PJ O'Neill BV Napolitano A Bullmore ET Neuropsychiatric adverse effects of centrally acting antiobesity drugs CNS Neurosci Ther 2011 17 490 505 21951371
10 Dixon JB Dixon ME O'Brien PE Depression in association with severe obesity: changes with weight loss Arch Intern Med 2003 163 2058 2065 14504119
11 Fakhoury WK Wright D Wallace M Prevalence and extent of distress of adverse effects of antipsychotics among callers to a United Kingdom National Mental Health Helpline Int Clin Psychopharmacol 2001 16 153 162 11354237
12 Gitlin MJ Cochran SD Jamison KR Maintenance lithium treatment: side effects and compliance J Clin Psychiatry 1989 50 127 131 2925600
13 Kaplan LM Pharmacologic therapies for obesity Gastroenterol Clin North Am 2010 39 69 79 20202580
14 Rothman RB Baumann MH Dersch CM Romero DV Rice KC Carroll FI Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin Synapse 2001 39 32 41 11071707
15 Ioannides-Demos LL Proietto J McNeil JJ Pharmacotherapy for obesity Drugs 2005 65 1391 1418 15977970
16 Greenway FL Caruso MK Safety of obesity drugs Expert Opin Drug Saf 2005 4 1083 1095 16255666
17 Ioannides-Demos LL Piccenna L McNeil JJ Pharmacotherapies for obesity: past, current, and future therapies J Obes 2011 2011 179674 21197148
18 John CE Jones SR Voltammetric characterization of the effect of monoamine uptake inhibitors and releasers on dopamine and serotonin uptake in mouse caudate-putamen and substantia nigra slices Neuropharmacology 2007 52 1596 1605 17459426
19 Franken IH Booij J van den Brink W The role of dopamine in human addiction: from reward to motivated attention Eur J Pharmacol 2005 526 199 206 16256105
20 Taber KH Black DN Porrino LJ Hurley RA Neuroanatomy of dopamine: reward and addiction J Neuropsychiatry Clin Neurosci 2012 24 1 4 22450608
21 Cruickshank CC Dyer KR A review of the clinical pharmacology of methamphetamine Addiction 2009 104 1085 1099 19426289
22 Nakagawa T Kaneko S Neuropsychotoxicity of abused drugs: molecular and neural mechanisms of neuropsychotoxicity induced by methamphetamine, 3,4-methylenedioxymethamphetamine (ecstasy), and 5-methoxy-N,N-diisopropyltryptamine (foxy) J Pharmacol Sci 2008 106 2 8 18198474
23 Hendricks EJ Greenway FL A study of abrupt phentermine cessation in patients in a weight management program Am J Ther 2011 18 292 299 20592662
24 Glatz AC Ehrlich M Bae RS Clarke MJ Quinlan PA Brown EC Inhibition of cocaine self-administration by fluoxetine or D-fenfluramine combined with phentermine Pharmacol Biochem Behav 2002 71 197 204 11812523
25 Alexander M Rothman RB Baumann MH Endres CJ Brasić JR Wong DF Noradrenergic and dopaminergic effects of (+)-amphetamine-like stimulants in the baboon Papio anubis Synapse 2005 56 94 99 15729739
26 Moreira R The efficacy and tolerability of bupropion in the treatment of major depressive disorder Clin Drug Investig 2011 31 Suppl 1 5 17
27 Teva Pharmaceuticals USA Adipex-P drug label 2012 cited 2012 Jul 1 Available from http://www.adipex.com/contents/pdf/Adipex_pi.pdf
28 Raison CL Klein HM Psychotic mania associated with fenfluramine and phentermine use Am J Psychiatry 1997 154 711 9137134
29 Bostwick JM Brown TM A toxic reaction from combining fluoxetine and phentermine J Clin Psychopharmacol 1996 16 189 190 8690835
30 Cleare AJ Phentermine, psychosis, and family history J Clin Psychopharmacol 1996 16 470 471 8959483
31 Zimmer JE Gregory RJ Bipolar depression associated with fenfluramine and phentermine J Clin Psychiatry 1998 59 383 384 9714271
32 Douglas A Douglas JG Robertson CE Munro JF Plasma phentermine levels, weight loss and side-effects Int J Obes 1983 7 591 595 6654575
33 Allison DB Gadde KM Garvey WT Peterson CA Schwiers ML Najarian T Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP) Obesity (Silver Spring) 2012 20 330 342 22051941
34 Food and Drug Administration Qsymia (phentermine and topiramate extended-release) capsules approval letter 2012 2012 cited 2012 Jul 1 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist
35 Rosenstock J Hollander P Gadde KM Sun X Strauss R Leung A OBD-202 Study Group A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients Diabetes Care 2007 30 1480 1486 17363756
36 Nisoli E Carruba MO An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action Obes Rev 2000 1 127 139 12119986
37 Halford JC Wanninayake SC Blundell JE Behavioral satiety sequence (BSS) for the diagnosis of drug action on food intake Pharmacol Biochem Behav 1998 61 159 168 9738531
38 Connoley IP Liu YL Frost I Reckless IP Heal DJ Stock MJ Thermogenic effects of sibutramine and its metabolites Br J Pharmacol 1999 126 1487 1495 10217544
39 Food and Drug Administration FDA Drug Safety Communication: FDA recommends against the continued use of Meridia (sibutramine) 2010 Available from: http://www.fda.gov/Drugs/DrugSafety/ucm228746.htm
40 Bymaster FP Dreshfield-Ahmad LJ Threlkeld PG Shaw JL Thompson L Nelson DL Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors Neuropsychopharmacology 2001 25 871 880 11750180
41 Naik S Khoo CL Lua R Chai SB Liew A Sim K Recurrent episodes of brief affective psychosis induced by sibutramine Prog Neuropsychopharmacol Biol Psychiatry 2010 34 1359 1360 20643178
42 Cordeiro Q Vallada H Sibutramine-induced mania episode in a bipolar patient Int J Neuropsychopharmacol 2002 5 283 284 12366881
43 Benazzi F Organic hypomania secondary to sibutramine-citalopram interaction J Clin Psychiatry 2002 63 165 11874219
44 Rocha FF Bamberg TO Pinto FC Gomes LM Silveira S Hypomanic episode secondary to sibutramine in a patient with type-I bipolar disorder Rev Bras Psiquiatr 2008 30 400 401 19142420
45 Elfhag K Rössner S Barkeling B Rooth P Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood Pharmacol Res 2005 51 159 163 15629262
46 Kiortsis DN Tsouli S Filippatos TD Konitsiotis S Elisaf MS Effects of sibutramine and orlistat on mood in obese and overweight subjects: a randomised study Nutr Metab Cardiovasc Dis 2008 18 207 210 17570651
47 Abott Laboratories Sibutramine drug label 2010 2010 cited 2012 Jul 1 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/020632s034s035lbl.pdf
48 Perrio MJ Wilton LV Shakir SA The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England Obesity (Silver Spring) 2007 15 2712 2722 18070762
49 McElroy SL Frye MA Altshuler LL Suppes T Hellemann G Black D A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders Bipolar Disord 2007 9 426 434 17547588
50 Shakir SAW Strom BL Prescription-event monitoring Textbook of pharmacoepidemiology 2005 4th ed Chichester John Wiley & Sons 203 216
51 Faulconbridge LF Wadden TA Berkowitz RI Sarwer DB Womble LG Hesson LA Changes in symptoms of depression with weight loss: results of a randomized trial Obesity (Silver Spring) 2009 17 1009 1016 19197266
52 Heal DJ Gosden J Smith SL What is the prognosis for new centrally-acting anti-obesity drugs? Neuropharmacology 2012 63 132 146 22313529
53 Astrup A Toubro S Topiramate: a new potential pharmacological treatment for obesity Obes Res 2004 12 Suppl 167S 173S 15687413
54 Eliasson B Gudbjörnsdottir S Cederholm J Liang Y Vercruysse F Smith U Weight loss and metabolic effects of topiramate in overweight and obese type 2 diabetic patients: randomized double-blind placebo-controlled trial Int J Obes (Lond) 2007 31 1140 1147 17264849
55 Food and Drug Administration Belviq (lorcaserin hydrochloride) approval letter 2012 2012 cited 2012 Jul 1 Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory#apphist
56 Stahl SM Stahl's essential psychopharmacology: The prescriber's guide 2011 4th ed Cambridge Cambridge University Press
57 Sachs GS Lafer B Stoll AL Banov M Thibault AB Tohen M A double-blind trial of bupropion versus desipramine for bipolar depression J Clin Psychiatry 1994 55 391 393 7929019
58 Parikh SV LeBlanc SR Ovanessian MM Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) Can J Psychiatry 2010 55 136 143 20370963
59 Brown ES Carmody TJ Schmitz JM Caetano R Adinoff B Swann AC A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence Alcohol Clin Exp Res 2009 33 1863 1869 19673746
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.